Platinum-resistant refers to a type of cancer that does not respond to platinum-based chemotherapy drugs. Platinum-based drugs, such as cisplatin and carboplatin, are commonly used in the treatment of various cancers, including ovarian, lung, and testicular cancer. However, some cancers may develop resistance to these drugs, leading to treatment failure and disease progression. Research in the area of platinum-resistant cancer focuses on understanding the mechanisms of resistance, identifying biomarkers that can predict resistance, and developing alternative treatment strategies for these patients. This may involve exploring targeted therapies, immunotherapy, or combinations of different chemotherapy drugs to overcome platinum resistance and improve patient outcomes.